Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab
Pediatric Dermatology2023Vol. 41(1), pp. 5–11
Citations Over TimeTop 10% of 2023 papers
Sylvia Aidé Martínez‐Cabriales, Danielle Marcoux, Carmen Liy‐Wong, Vimal H. Prajapati, Cathryn Sibbald, Natalie Cunningham, Perla Lansang, Rochelle Tonkin, Marissa Joseph, Lauren Wong, Shanna Spring, Geneviève Gavigan, Michele Ramien
Abstract
Dupilumab is safe and effective for patients under the age of 12. However, even for experienced providers, access to the medication was challenging.
Related Papers
- → Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults(2020)22 cited
- → Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients(2024)8 cited
- → Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial(2018)4 cited
- Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.(2021)
- → 27431 Dupilumab treatment improves health-related quality of life in children aged ≥6 to <12 years with severe atopic dermatitis(2021)1 cited